Interagency Patent Coordination and Improvement Act of 2025
- Bill Number
- H.R. 4570
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Commerce
- Status
- Introduced
- Latest Action
- 2025-07-21: Referred to the House Committee on the Judiciary.
- Last Updated
- 2026-03-31T12:34:02Z
AI-Generated Summary
Purpose of the Legislation
The Interagency Patent Coordination and Improvement Act of 2025 aims to improve coordination between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on patent matters related to human drugs and biological products. It seeks to facilitate the sharing of information and technical assistance to enhance the accuracy and efficiency of patent examinations, while ensuring consistency in how companies represent their inventions to both agencies.
Key Provisions
- Short Title and Findings: The Act is titled the "Interagency Patent Coordination and Improvement Act of 2025." Congress identifies issues such as the relevance of FDA-held information to USPTO patent decisions, the need for consistent company submissions across agencies, benefits of shared data for assessing prior art (existing inventions or knowledge that could invalidate a patent), and encouragement for USPTO leadership to collaborate with other agencies.
- Report Requirement: Within 4 years of enactment, the USPTO Director must submit a report to the Senate and House Judiciary Committees detailing:
- How often FDA provides information to USPTO via the new task force and how it's used in patent reviews.
- The most useful methods and types of shared information.
- Recommendations for changes to the task force's mandate, funding, or operations.
- Opportunities for similar coordination with other federal agencies.
- Establishment of Interagency Task Force on Patents (added as new Section 14 to Title 35, U.S. Code):
- Structure: Composed of USPTO and FDA staff with expertise in operations, science, medicine, and related fields. The agencies must enter or update a memorandum of understanding (MOU) to outline task force duties.
- Activities:
- Regular meetings, workshops, and training to share processes for reviewing patent, drug, and product applications.
- Exchange of data on new patents, drug approvals, technologies, prior art, and scientific trends (on a case-by-case basis).
- Processes for USPTO to request and FDA to provide timely information on drug approvals, labeling updates, and non-public data (e.g., communications with drug sponsors) to aid patent examiners in verifying claims like whether an invention was already on sale.
- USPTO assistance to FDA in its routine task of listing patents for approved drugs.
- FDA consultation with USPTO on specific patent applications or rejections when requested.
- Limitations: The task force does not interfere with FDA's routine patent-listing role or affect patent enforcement in lawsuits.
- Confidentiality Protections:
- Shared confidential information (e.g., trade secrets) remains protected as if held by the originating agency.
- Protocols require notice to drug sponsors before sharing their data (with 30 days for consultation), separation of shared info from public patent files, and procedures to prevent accidental leaks.
- Remedies for any unauthorized disclosures are to be identified, without overriding existing legal protections.
- Amendment to Existing Law: Updates Section 2(c) of Title 35, U.S. Code, to require USPTO consultation with FDA through the task force for patent decisions on human drugs and biological products.
Significant Changes to Existing Law
- Introduces a formal interagency task force (new Section 14) to enable structured information sharing, which was previously informal or limited.
- Mandates USPTO-FDA consultation for drug- and biologics-related patents, expanding the USPTO Director's duties under Section 2(c).
- Establishes specific processes for accessing non-public FDA data during patent exams, while adding safeguards to maintain confidentiality—changes that build on but do not alter core agency functions like FDA's ministerial patent-listing role.
- Requires a future report to evaluate and potentially expand coordination, promoting ongoing improvements.
Potential Impacts
- On Government Agencies: Enhances efficiency for USPTO by providing patent examiners with better access to FDA data, potentially speeding up reviews and reducing errors in assessing drug-related inventions. FDA gains USPTO support for patent listing, but both must invest in protocols, meetings, and staff time, with possible funding needs identified in the report.
- On Citizens and Businesses: Pharmaceutical companies and inventors may face more consistent regulatory scrutiny, leading to stronger patents but also higher compliance burdens (e.g., responding to data-sharing notices). The public could benefit from more reliable patents on drugs, potentially accelerating innovation in healthcare without direct cost to individuals.
- On International Relations: No direct impacts mentioned; the focus is domestic agency coordination, though improved U.S. patent processes could indirectly strengthen global competitiveness in biotech.
Main Stakeholders Affected
- USPTO and FDA: Primary operators, including directors, examiners, and scientific staff responsible for implementing the task force and sharing data.
- Pharmaceutical and Biotech Companies: Sponsors of human drugs and biological products, who submit applications to both agencies and must be notified of data sharing, affecting their intellectual property strategies.
- Patent Applicants and Inventors: Especially those in the drug sector, who may experience more informed (and potentially stricter) patent examinations.
- Congress: Receives the required report to oversee and potentially adjust the task force.
- Broader Federal Agencies: Identified in the report for future coordination opportunities, such as those holding scientific or technical data.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces protections for confidential information under existing laws (e.g., trade secret statutes), emphasizing that sharing does not waive privacy rights or alter FDA's neutral role in patent listing. It promotes accurate patent validity checks (e.g., under Section 102 for prior sales) without expanding USPTO authority into FDA's domain, avoiding potential jurisdictional conflicts.
- Constitutional: Aligns with Congress's power to regulate patents (Article I, Section 8) by fostering interagency efficiency, with no apparent free speech or due process concerns due to built-in notice and remedy provisions.
- Political: Encourages bureaucratic collaboration to address recognized gaps in federal information sharing, potentially setting a model for other agencies. It could face debate over resource allocation or industry influence, but the bill's neutrality on patent enforceability limits controversy.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-07-21: Referred to the House Committee on the Judiciary.
- 2025-07-21: Introduced in House
- 2025-07-21: Introduced in House
Bill Versions
- Interagency Patent Coordination and Improvement Act of 2025 — issued 2025-07-21 — PDF (10 pages)